TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI Budget of $1.4 Billion Seems Assured, Barring GRH Cut, Veto; Organ Systems Renewal Confirmed October 17, 1986
TCL Archive New Treatment For Malignant Glioma, IL13-PE38, Tested In Early Clinical Trials December 28, 2001
